Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 ADC”

113 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 113 results

Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Large-scale testing (Phase 3)Active Not RecruitingNCT03529110
What this trial is testing

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Who this might be right for
Breast Cancer
Daiichi Sankyo 524
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05350917
What this trial is testing

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Who this might be right for
HER2-positive or Mutated Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University 20
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Early research (Phase 1)Study completedNCT03366428
What this trial is testing

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Who this might be right for
Malignant Neoplasm of Breast
Daiichi Sankyo Co., Ltd. 51
Large-scale testing (Phase 3)Active Not RecruitingNCT05980481
What this trial is testing

RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
RemeGen Co., Ltd. 201
Testing effectiveness (Phase 2)Study completedNCT04132960
What this trial is testing

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

Who this might be right for
Breast Tumors
UNICANCER 186
Early research (Phase 1)Study completedNCT03523572
What this trial is testing

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Who this might be right for
Breast CancerUrothelial Carcinoma
Daiichi Sankyo 86
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05356351
What this trial is testing

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Who this might be right for
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
Tianjin Medical University Cancer Institute and Hospital 30
Early research (Phase 1)Study completedNCT03383692
What this trial is testing

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Who this might be right for
Neoplasm Metastasis
Daiichi Sankyo Co., Ltd. 40
Testing effectiveness (Phase 2)UnknownNCT04965519
What this trial is testing

RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Who this might be right for
Gynecological Malignancy
RemeGen Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06155396
What this trial is testing

RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
RemeGen Co., Ltd. 116
Not applicableLooking for participantsNCT07379268
What this trial is testing

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Who this might be right for
Bladder Cancer
Qilu Hospital of Shandong University 224
Early research (Phase 1)Ended earlyNCT03284723
What this trial is testing

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Who this might be right for
Breast Neoplasms
Pfizer 95
Early research (Phase 1)Study completedNCT02881138
What this trial is testing

RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Who this might be right for
Solid Tumors
RemeGen Co., Ltd. 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 135
Large-scale testing (Phase 3)UnknownNCT04714190
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 351
Testing effectiveness (Phase 2)Looking for participantsNCT06560528
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)Study completedNCT03052634
What this trial is testing

RC48-ADC in Subjects With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RemeGen Co., Ltd. 112
Load More Results